<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2460">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129137</url>
  </required_header>
  <id_info>
    <org_study_id>UP-CLI-2019-001</org_study_id>
    <nct_id>NCT05129137</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)</brief_title>
  <acronym>ARL/20/277</acronym>
  <official_title>Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg) and Individual Nefopam Hydrochloride and Paracetamol Taken Alone or Concomitantly After Oral Single Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unither Pharmaceuticals, France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accutest Research Laboratories (I) Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Unither Pharmaceuticals, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the pharmacokinetic profile of a Fixed Dose Combination nefopam&#xD;
      hydrochloride (30 mg) / paracetamol (500 mg) and individual components taken alone or&#xD;
      concomitantly after oral single dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>An open-label, randomized, four-period, four treatments, cross-over trial in healthy volunteers</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nefopam and Paracetamol Pharmacokinetic profiles in each arms after single dose</measure>
    <time_frame>up to 48 hours post dose</time_frame>
    <description>Peak Plasma Concentration (Cmax) of nefopam hydrochloride and paracetamol after single dose at different timepoints : Within 60 min before drug administration),0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nefopam and Paracetamol Pharmacokinetic profiles in each arms after single dose</measure>
    <time_frame>up to 48 hours post dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of nefopam hydrochloride and paracetamol after single dose at different timepoints : Within 60 min before drug administration),0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Paracetamol metabolites Pharmacokinetic profiles in each arms after single dose</measure>
    <time_frame>up to 48 hours post dose</time_frame>
    <description>Peak Plasma Concentration (Cmax) of main paracetamol metabolites (Sulfate and Glucuronide) after single dose at different timepoints : Within 60 min before drug administration),0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol metabolites Pharmacokinetic profiles in each arms after single dose</measure>
    <time_frame>up to 48 hours post dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of main paracetamol metabolites (Sulfate and Glucuronide) after single dose at different timepoints : Within 60 min before drug administration),0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-desmethyl-nefopam Pharmacokinetic profiles in each arms after single dose</measure>
    <time_frame>up to 48 hours post dose</time_frame>
    <description>Peak Plasma Concentration (Cmax) of N-desmethyl-nefopam after single dose at different timepoints : Within 60 min before drug administration),0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-desmethyl-nefopam Pharmacokinetic profiles in each arms after single dose</measure>
    <time_frame>up to 48 hours post dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of N-desmethyl-nefopam after single dose at different timepoints : Within 60 min before drug administration),0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Occurrence and severity of adverse events (serious and non-serious adverse events)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>FDC nefopam hydrochloride 30mg / paracetamol 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose: 2 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nefopam hydrochloride 30mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose: 2 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paracetamol 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose: 2 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nefopam hydrochloride 30mg and paracetamol 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose: 2 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nefopam hydrochloride 30mg X2</intervention_name>
    <description>nefopam hydrochloride 30mg X2</description>
    <arm_group_label>nefopam hydrochloride 30mg</arm_group_label>
    <arm_group_label>nefopam hydrochloride 30mg and paracetamol 500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol 500 mg X2</intervention_name>
    <description>paracetamol 500 mg X2</description>
    <arm_group_label>nefopam hydrochloride 30mg and paracetamol 500mg</arm_group_label>
    <arm_group_label>paracetamol 500mg</arm_group_label>
    <other_name>acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2</intervention_name>
    <description>Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2</description>
    <arm_group_label>FDC nefopam hydrochloride 30mg / paracetamol 500mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and non-pregnant female human subjects, age 18 - 45 years.&#xD;
&#xD;
          -  Body Mass Index between 18.5-30 Kg / m2 .&#xD;
&#xD;
          -  Subjects with normal findings .&#xD;
&#xD;
          -  Willingness to follow the protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of hypersensitivity to Nefopam, Paracetamol or related drugs.&#xD;
&#xD;
          -  Requiring medication for any ailment having enzyme-modifying activity in the previous&#xD;
             28 days, prior to dosing day.&#xD;
&#xD;
          -  Subjects with a history of convulsive disorders.&#xD;
&#xD;
          -  Subject with a moderate or severe renal impairment&#xD;
&#xD;
          -  History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,&#xD;
             metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric&#xD;
             diseases.&#xD;
&#xD;
          -  Female subjects not confirming to using birth control measures,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pramila Yadav, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accutest Research Laboratories</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CRO's office</last_name>
    <phone>0091 22 2778 0718</phone>
    <email>clinicaltrials@unither-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Accutest Research Laboratories</name>
      <address>
        <city>Navi Mumbai</city>
        <zip>400709</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

